Market Overview

UPDATE: J.P. Morgan Lowers Alkermes' PT

Related ALKS
Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic
US Stock Futures Rise Ahead Of Economic Data

According to a research report published this morning, J.P. Morgan has lowered Alkermes' (NASDAQ: ALKS) PT from $24 to $23.

In the report, J.P. Morgan said, "Post close, Alkermes announced the discontinuation of ALKS-37 (for opioid induced constipation, or OIC) after the product did not exceed management's internal threshold in Phase 2b to warrant continued development into a pivotal Phase 3 program. Overall, we view this is a modest setback to the company's pipeline, and we are not expecting a significant response in the stock. Our model had only assumed a 25% probability of success. Removing this potential call option results in our Dec 2012 PT dropping to $23 from $24."

Alkermes closed yesterday at $16.58.

Latest Ratings for ALKS

DateFirmActionFromTo
Apr 2014Mizuho SecuritiesUpgradesNeutralBuy
Apr 2014Credit SuisseInitiates Coverage onOutperform
Jan 2014Goldman SachsMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters